VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Aged 18 years or older                             │ Aged 18 years or older                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously taken one or more statins               │ Previously taken one or more statins               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Withdrawn from statins because of perceived side   │ Withdrawn from statins because of perceived side   │     100 │
│ effects                                            │ effects                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Developed side effects within 2 weeks of           │ Developed side effects within 2 weeks of           │     100 │
│ initiation                                         │ initiation                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical indication for statins for primary or     │ Clinical indication for statins for primary or     │     100 │
│ secondary prevention of cardiovascular disease or  │ secondary prevention of cardiovascular disease or  │         │
│ dyslipidaemia, on either no medication or non-     │ dyslipidaemia, on either no medication or non-     │         │
│ statin lipid lowering therapy (e.g, ezetimibe)     │ statin lipid lowering therapy (e.g, ezetimibe)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of neuropathy                              │ History of neuropathy                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Regularly taking prescribed analgesia              │ Regularly taking prescribed analgesia              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of a chronic pain condition                │ History of a chronic pain condition                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of severe mental illness (as their         │ History of severe mental illness (as their         │     100 │
│ experience of symptoms may already be altered)     │ experience of symptoms may already be altered)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of fibrates (because of the risk of    │ Current use of fibrates (because of the risk of    │     100 │
│ interaction with statins but will not exclude      │ interaction with statins but will not exclude      │         │
│ participants taking ezetimibe)                     │ participants taking ezetimibe)                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe previous reaction or reaction considered    │ Severe previous reaction or reaction considered    │     100 │
│ immunological, such as anaphylaxis, facial         │ immunological, such as anaphylaxis, facial         │         │
│ swelling, severe rash, muscle ache with rise in    │ swelling, severe rash, muscle ache with rise in    │         │
│ serum creatine kinase, inflammatory myopathy,      │ serum creatine kinase, inflammatory myopathy,      │         │
│ rhabdomyolysis or liver function abnormalities     │ rhabdomyolysis or liver function abnormalities     │         │
│ (aspartate transaminase (AST) or alanine           │ (aspartate transaminase (AST) or alanine           │         │
│ transaminase (ALT) greater than 3 times upper      │ transaminase (ALT) greater than 3 times upper      │         │
│ limit or normal)                                   │ limit or normal)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Side-effects taking longer than 2 weeks to develop │ Side-effects taking longer than 2 weeks to develop │     100 │
│ (because in such participants much longer blocks   │ (because in such participants much longer blocks   │         │
│ of treatment would be required, if the present     │ of treatment would be required, if the present     │         │
│ study is positive such studies will be planned for │ study is positive such studies will be planned for │         │
│ the future)\*                                      │ the future)*                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of statin intolerance with drug            │ History of statin intolerance with drug            │     100 │
│ interaction to antiretroviral drugs                │ interaction to antiretroviral drugs                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of statin intolerance to any other drug    │ History of statin intolerance to any other drug    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or breast feeding                         │ Pregnant or breast feeding                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Side effects taking longer than 2 weeks to present │ Side effects taking longer than 2 weeks to present │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In clinical judgement of study doctor, participant │ In clinical judgement of study doctor, participant │     100 │
│ should not participate                             │ should not participate                             │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                        │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Previously taken one or more statins │      41 │
╘═══════════════════════════════════╧══════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.72222222222223
OverAll Ratio: 97.86111111111111
